Skip to content

Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution & Oncologic Outcome

Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution During Elective Colorectal Cancer Surgery on the Oncologic Outcome

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02399059
Enrollment
106
Registered
2015-03-26
Start date
2011-01-31
Completion date
2015-03-31
Last updated
2015-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Tumors

Keywords

recurrence

Brief summary

Antibiotic lavage reduces bacterial contamination and decreases SSI infection rate. SSI leads to an immunocompromised situation, leaving unattended the neoplasm. It has been described that SSI may result in a worse oncologic outcome.

Detailed description

Antibiotics combined with lavage have demonstrated a reduction in the bacterial contamination and decreases SSI infection rate. SSI leads to an immunocompromised situation, as immunologic defense is focused on controlling the septic focus, leaving unattended the neoplasm. It has been described that SSI may result in a worse oncologic outcome. The aim of this study is to evaluate prospectively the effect of peritoneal lavage with clindamycin and gentamicin on the oncologic outcome of colorectal tumours.

Interventions

PROCEDUREAntibiotic lavage

Peritoneal irrigation with gentamycin-clindamycin solution

PROCEDURENormal saline lavage

Peritoneal irrigation with normal saline

Sponsors

Hospital General Universitario Elche
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* diagnosis of colon neoplasms * plans to undergo an elective surgery with curative aims

Exclusion criteria

* preoperative diagnosis of chronic renal failure (because of the risk of nephrotoxicity associated with intraperitoneal gentamicin absorption) * allergy to gentamicin or clindamycin.

Design outcomes

Primary

MeasureTime frame
Global survival36 months after intervention

Secondary

MeasureTime frame
Disease free survival36 months after intervention

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026